Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Lung Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Urinary Bladder Neoplasms 4Sarcoma, Alveolar Soft Part 3Carcinoma, Transitional Cell 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Urethral Neoplasms 2Ureteral Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Ovarian Neoplasms 2Glioblastoma 2Gallbladder Neoplasms 2Fallopian Tube Neoplasms 2Extensive Stage Lung Small Cell Carcinoma 2Colorectal Neoplasms 2Cholangiocarcinoma 2Carcinoma, Renal Cell 2Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Clear Cell 1Sarcoma 1Rhabdoid Tumor 1Recurrent Bladder Urothelial Carcinoma 1Papillary renal cell carcinoma, sporadic 1Oropharyngeal Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Mesothelioma, Malignant 1

Interventions

dehydroftorafur 1atezolizumab 1Specimen Handling 1Oxaliplatin 1Magnetic Resonance Spectroscopy 1Leucovorin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × DNA Repair-Deficiency Disorders × atezolizumab × Clear all
NCT02912559 2026-06-01

Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

National Cancer Institute (NCI)

Phase 3 Active not recruiting
712 enrolled 14 charts
Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, DNA Repair-Deficiency Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡